Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Assets (2023 - 2025)

Historic Assets for Immunome (IMNM) over the last 3 years, with Q3 2025 value amounting to $299.4 million.

  • Immunome's Assets rose 1653.54% to $299.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $299.4 million, marking a year-over-year increase of 1653.54%. This contributed to the annual value of $240.2 million for FY2024, which is 6173.49% up from last year.
  • According to the latest figures from Q3 2025, Immunome's Assets is $299.4 million, which was up 1653.54% from $296.3 million recorded in Q2 2025.
  • Over the past 5 years, Immunome's Assets peaked at $342.7 million during Q1 2025, and registered a low of $41.4 million during Q2 2023.
  • Over the past 3 years, Immunome's median Assets value was $256.9 million (recorded in 2024), while the average stood at $216.6 million.
  • In the last 5 years, Immunome's Assets surged by 61489.08% in 2024 and then rose by 2.53% in 2025.
  • Quarter analysis of 3 years shows Immunome's Assets stood at $148.5 million in 2023, then skyrocketed by 61.73% to $240.2 million in 2024, then grew by 24.62% to $299.4 million in 2025.
  • Its Assets was $299.4 million in Q3 2025, compared to $296.3 million in Q2 2025 and $342.7 million in Q1 2025.